drugset / Trial / NCT03669757

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis

NCT03669757

Phase 1 Completed 13 enrolled LEO Pharma
RandomizedParallel-groupSingle-blindTreatment

Summary

To assess safety and tolerability after treatment with LEO 134310 cutaneous solution.

Timeline

Start
2018-09-27
Primary completion
2019-02-01
Completion
2019-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject LEO 134310 Unknown Topical
Comparator betamethasone valerate Small molecule 0.1 % Topical

Indications